Long-term virological outcome in patients infected with multi- nucleoside analogue-resistant HIV-1

Philippe Clevenbergh; Myriam Kirstetter; Jean Yves Liotier; Michel Dupon; Patrick Philibert; Christine Jacomet; Eric Cua; Nathalie Montagne; Jean Claude Schmit; Pierre Dellamonica

Long-term virological outcome in patients infected with multi- nucleoside analogue-resistant HIV-1

Philippe Clevenbergh^*, Myriam Kirstetter, Jean Yves Liotier, Michel Dupon, Patrick Philibert, Christine Jacomet, Eric Cua, Nathalie Montagne, Jean Claude Schmit, Pierre Dellamonica

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

The emergence of HIV strains that are resistant to antiretroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.

Original language	English
Pages (from-to)	305-308
Number of pages	4
Journal	Antiviral Therapy
Volume	7
Issue number	4
Publication status	Published - Dec 2002
Externally published	Yes

Cite this

@article{8eb4ebd3d9894f2ba619ca68ed3afa69,

title = "Long-term virological outcome in patients infected with multi- nucleoside analogue-resistant HIV-1",

abstract = "The emergence of HIV strains that are resistant to antiretroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.",

author = "Philippe Clevenbergh and Myriam Kirstetter and Liotier, {Jean Yves} and Michel Dupon and Patrick Philibert and Christine Jacomet and Eric Cua and Nathalie Montagne and Schmit, {Jean Claude} and Pierre Dellamonica",

year = "2002",

month = dec,

language = "English",

volume = "7",

pages = "305--308",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "Sage Publications",

number = "4",

}

TY - JOUR

T1 - Long-term virological outcome in patients infected with multi- nucleoside analogue-resistant HIV-1

AU - Clevenbergh, Philippe

AU - Kirstetter, Myriam

AU - Liotier, Jean Yves

AU - Dupon, Michel

AU - Philibert, Patrick

AU - Jacomet, Christine

AU - Cua, Eric

AU - Montagne, Nathalie

AU - Schmit, Jean Claude

AU - Dellamonica, Pierre

PY - 2002/12

Y1 - 2002/12

N2 - The emergence of HIV strains that are resistant to antiretroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.

AB - The emergence of HIV strains that are resistant to antiretroviral drugs is a major cause of treatment failure. Two sets of mutations: the Q151M complex and the 69 insert, cause resistance to multiple nucleoside analogues. We report the response to treatment in 12 patients with multiple NRTI-resistant HIV-1 strains. Seven of 12 patients (58%) were able to maintain a viral load below 200 copies/ml at week 48. The patients most likely to obtain therapeutic success were those having no or low-level resistance to non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. New and more effective drugs are needed for patients with HIV-1 that is resistant to more than one of the current three classes of HIV drugs.

UR - http://www.scopus.com/inward/record.url?scp=0036974993&partnerID=8YFLogxK

M3 - Article

C2 - 12553486

AN - SCOPUS:0036974993

SN - 1359-6535

VL - 7

SP - 305

EP - 308

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 4

ER -

Long-term virological outcome in patients infected with multi- nucleoside analogue-resistant HIV-1

Abstract

Other files and links

Fingerprint

Cite this